cyrilzakka/clinical-trials huggingface dataset:
USG Guided ESP Block in Spinal Surgery

American Society of Anaesthesiologist physical status I-II, aged between 18-65, 40 patients which underwent lumbar spinal surgery will recruited to this study. These subjects will Ultrasound (USG) guided erector spinae block will perform at T10 level (bilaterally) to the all patient under general anaesthesia. 15 ml bupivacaine %0.5 and 5 ml lidocaine %2 will use for USG guided ESP block. 0.1 microgram/kg morphine will apply intravenously and diclofenac Na 75 mg intramuscularly will apply at last 30 minutes of surgery postoperative analgesia to all patients. Postoperative pain assessment will perform with visual analog scale (VAS)

American Society of Anaesthesiologist physical status I-II, aged between 18-65, 40 patients which underwent lumbar spinal surgery will recruited to this study. The patients were randomly allocated into two groups (1:1), via a computer-generated randomization list. Ultrasound (USG) guided erector spinae block will perform at T10 level (bilaterally) to the 20 patients under general anaesthesia in Group E and same volume saline will apply to the ESP block region at T10 level for control group (Group C). Total intravenous anaesthesia (propofol+remifentanil) will perform to the all patients. 15 ml bupivacaine %0.5 and 5 ml lidocaine %2 will use for USG guided ESP block. 0.1 microgram/kg morphine intravenously and diclofenac Na 75 mg intramuscularly will apply for postoperative analgesia to the all patients at last 30 minutes of surgery. Postoperative pain assessment will perform with visual analog scale (VAS). VAS, morphine consumption and complications will record. The rescue analgesic 0.4 mg/kg mepheridine will administer intravenously whenever the patient requested to the analgesic. Diclofenac sodium 75 mg will repeat to the all patients at the 12th of postoperative period, intramuscularly.

Eligibility Criteria:
Inclusion Criteria:

* accepting to participate the study
* ASA I-II patients
* The patients underwent spinal surgery

Exclusion Criteria:

* Non Volunteers
* ASA III and over
* Renal and hepatic failure
* Emergency surgical procedures
Impact of Different Techniques on The Efficacy of Anaesthesia in Mandibular Molars With Acute Irreversible Pulpitis

The goal of this clinical trial is to assess the effect of

* Preoperative intraligamentary corticosteroids injection
* Cryotherapy which is cold application on :

  * Hard tooth structure ( crown of the tooth )
  * Soft tissue overlying roots on the efficacy of the inferior alveolar nerve block anaesthesia in patients with mandibular molars with symptomatic irreversible pulpitis. The main question it aims to answer are: • Does intraligamentary dexamethazone injection increase the success rate of inferior alveolar nerve block without the need for oral premedication.

Participants will describe their preoperative pain level to the investigator and describe their pain level during the treatment.

Researchers will compare cryotherapy to see if it increases the success rate of inferior alveolar nerve block.


Eligibility Criteria:
Inclusion Criteria:

* Participants willing to commit for the entire period of the trial and agreed to sign the written consent after full explanation of the study.
* Having a mandibular molar tooth diagnosed with symptomatic irreversible pulpitis (hot tooth - vital pulp, intermittent or continuous sharp pain that lasts longer after removal of the stimulus).

Exclusion Criteria:

* Presence of any systemic disease or allergic reactions.
* Vulnerable group; prisoners, pregnant females, mentally ill, etc...
* The presence of a periapical radiolucency.
* Teeth with open apices.
* A previous root canal treatment.
* Sinus tracts.
* Local gum swelling around the affected tooth.
* Severe periodontal disease .
* Presence of periodontal pockets \>3 mm in the affected tooth.
* Absence of bleeding in the pulp chamber on access cavity preparation.
* Patients with doubted diagnosis due to multiple carious teeth.
Anti Cancer Stem Cell Activity of Pre-operative Bevacizumab and Chemotherapy in Breast Cancer

The purpose of this study is to evaluate anti-cancer stem cell (CSC) activity (measured by the amount of Aldehyde dehydrogenase 1/ALDH1+ cells before and after treatment) of pre-operative bevacizumab in combination with conventional chemotherapy in breast cancer receiving neo-adjuvant treatment, compared to a control arm receiving chemotherapy alone.


Eligibility Criteria:
Inclusion Criteria:

* Women older than 18 ys
* Primary breast cancer treated in the neoadjuvant setting (synchronous metastatic disease are eligible)
* Primary breast tumor accessible to initial biopsy
* White Blood Count \> 3.000/µl and Absolute neutrophil count ≥ 1.500/µl AND platelets ≥ 100 x 109/L AND Hemoglobin ≥ 9 g/dL, Serum creatinine ≤ 150µm/l• Urine dipstick for proteinuria \< 2+. Patients discovered to have ≥ 2+ proteinuria on dipstick urinalysis at baseline should undergo a 24 hour urine collection and must demonstrate ≤ 1 g of protein in 24 hours, Total bilirubin ≤ 1.5 ULN and ASAT \< 2.5 ULN AND ALAT \< 1.5 ULN (2.5 if liver metastasis), Adequate coagulation function: International normalized ratio (INR) ≤ 1.5 and TCA ≤ 1.5 x ULN
* Left ventricular ejection fraction (LVEF) ≥ 55% (isotopic or
* ultrasound methods)
* Karnofsky Index \> 1 ; Performance status 0 to 1
* Patients must have signed a written informed consent form prior to any study specific screening procedures
* Patient affiliated to the national "Social Security" regimen or beneficiary of this regimen.

Exclusion Criteria:

* Previous history of cancer (other than curatively treated basal and squamous cell carcinoma of the skin and/or in-situ carcinoma of the cervix) relapsing within the 5 years before study entry
* Known contra-indication to anticancer compounds used
* Uncontrolled hypertension (systolic \>150 mmHg and/or diastolic \>100 mmHg) or history of hypertensive encephalopathy
* History of inherited diathesis or recent thrombotic events
* Non-healing wound, active peptic ulcer or bone fracture.
* Major surgery or significant traumatic injury within 28 days prior to study treatment start
* History of abdominal fistula, trachea-oesophageal fistula or urinary fistula
* Use of Non Steroid Anti Inflammatory or full dose anticoagulants or antiaggregation treatments within 10 days
* Pregnancy and breast feeding, premenopausal patient and no effective contraception
* Brain metastasis.
* Any unstable severe disease such as : uncontrolled cardiac or vascular disease, uncontrolled hemorrhagy, uncontrolled neuropsychiatric disorders, including dementia, uncontrolled infection or any severe disorders that may preclude study participation
* Patient considered geographically, socially or psychologically unable to comply with the treatment and the required medical follow-up.
Conservative Endometrioma Surgery

To study which surgical technique offers better results in treating endometriomas in terms of ovarian reserve preservation.

The 2 conservatives techniques used are:

1. The combined technique
2. CO2 laser vaporization only

Ovarian reserve will be assessed by consecutive measurements of AMH serum levels before and after surgery.


Eligibility Criteria:
Population: patients planned for laparoscopic CO2 laser surgery for endometriotic cysts.

Inclusion Criteria:

* Age: 18 - 40 years (both inclusive)
* Unilateral endometriotic cysts with a mean diameter of \>=2.5cm and ≤8 cm, measured in 3 dimensions.
* Presence of a contralateral endometrioma of ≤ 2cm is allowed
* Complaining of infertility and/or pain
* BMI ≤35
* Use of contraception (combined or Progesteron only) for at least 4 weeks before surgery

Exclusion Criteria:

* Incomplete surgery for the pelvis
* Contra-indication for the use of contraception (combined or Progesteron only)
* Use of GnRH analogues preoperatively and in the first 3 months postoperatively
* (History of) hysterectomy
* Prior unilateral oophorectomy
* Pituitary/hypothalamic disorders
* Suspected malignancy
* Contralateral endometrioma of \>2 cm
* AMH \<0.7 preoperatively
* Pregnancy
Evaluation of the Efficiency of Two Different Teaching Methods in Safe Subcutaneous Injection Skills

Subject: Subcutaneous (SC) insulin injection is frequently used in the treatment of Type 2 Diabetes patients. Complications such as pain, ecchymosis, hematoma, lipoatrophy and lipohypertrophy are frequently observed after SC injections. These complications that develop due to incorrect injection application negatively affect the use of injection application areas, change body image and negatively affect drug absorption. In order to reduce and prevent complications related to SC insulin injection, it is very important to gain the skill of safe SC insulin injection. It is stated that there are a limited number of studies on which of the teaching methods used in sick individuals are effective. In the national and international literature, no study has been found evaluating the effect of SC injection skill teaching based on video-supported training and low-fidelity simulation model applications on disease management in individuals diagnosed with Type 2 Diabetes Mellitus. In this regard, the research was planned as an experimental design in order to examine the effectiveness of video-supported training and low-fidelity simulation model-based teaching in gaining safe insulin injection skills via SC. For this purpose; It is aimed to evaluate the effect of two different skill teaching methods on the patient's SC injection ability, complication management and blood glucose level.

Purpose: This research was planned as an experimental design to examine the effectiveness of two different teaching methods (video-supported training and low-fidelity simulation model) in gaining safe insulin injection skills via the Subcutaneous (SC) route.

Design: A pretest-posttest two-group, quasi-experimental design will be used in the study.


Eligibility Criteria:
Inclusion Criteria:

* The patient must be 18 years of age or older,
* Have the physical and mental ability to accurately evaluate the Visual Analog Scale (VAS),
* The platelet count is 100 000/mm3 and above,
* Having a diagnosis of Type 2 Diabetes Mellitus,
* No dementia according to Mini-Cog test evaluation,
* The plan was to agree to participate in the study.

Exclusion Criteria:

* Having verbal and auditory problems,
* Using oral or SC anticoagulant
* Presence of any findings such as scarring, incision, ecchymosis, hematoma, lipoarthrrophy and lipohypertrophy on the skin in the area where the injection will be made,
* Recurrent use of drugs that affect the formation of lipoatrophy and lipohypertrophy, such as octroid, corticosteroid, and antiretroviral therapy,
* It was defined as having a diagnosis of Diabetes during pregnancy.
Stereotaxis and Chronic Total Occlusion

Wire-crossing of a chronic total coronary occlusion (CTO) is time-consuming and limited by the amount of contrast agent and time of radiation exposure. Magnetic wire navigation might accelerate wire-crossing by maintaining a coaxial vessel orientation. This study compares magnetic with conventional wire navigation for recanalization of CTOs.


Eligibility Criteria:
Inclusion Criteria:

* symptomatic
* preserved wall motion or viable myocardium
* chronic total occlusion

Exclusion Criteria:

* chronic renal failure
* prior allergic reactions against contrast agent
* hyperthyreosis
* claustrophobia
* pregnancy
* contraindications to aspirin or clopidogrel
Value of Transthoracic Ultrasonography (TTU) for Etiological Diagnosis of Acute Dyspnea: Cross Sectional Study

Evaluating the capability and efficiency of transthoracic ultrasound in attempting to identify the etiology of acute dyspnea.

Acute dyspnea is a frequent challenge for physicians due to having multiple etiologies, leading to difficulty in establishing an accurate diagnosis.

The presence of this symptom is already a predictor of increased mortality and a lot of investigations are required to differentiate between etiologies. Hence, prompt diagnosis is needed to streamline these patients' appropriate management and disposition from the ED.

Transthoracic ultrasound has traditionally been used for the detection of pleural effusion and evaluation of the chest wall, but the indications have been expanded.

The gold standard imaging technique for the majority of pulmonary disorders is high-resolution computed tomography (HRCT), but it has negatives which are:

* hazard of ionizing radiation
* high cost
* being nonportable

Eligibility Criteria:
Inclusion Criteria:

* Clinical history of acute dyspnea

Exclusion Criteria:

* Subcutaneous emphysema.
* Patients with more than 24 h interval between HRCT and TTU.
* Patients with poor-quality of TTU image.
Satisfaction With XEN Gel Stent Versus Trabeculectomy for the Treatment of Glaucoma

This is a prospective, observational, non-interventional study of patients scheduled to receive surgical intervention either via XEN or trabeculectomy for open-angle glaucoma. The decision to treat patients with a particular surgical procedure will not be influenced by the study as the treatment decision will continue to be made by the patient and the clinician. There will be no study mandated visits or treatments.


Eligibility Criteria:
Inclusion Criteria:

* Diagnosed with OAG (Open Angle Glaucoma) and using at least 2 topical IOP-lowering medication classes in the study eye
* Scheduled to receive surgical treatment with either XEN (Xen gel stent) or trabeculectomy in the study eye
* Access to an electronic device with internet capabilities and an email address for completion of PROs (Patient Reported Outcomes)
* Be willing and able to complete PROs (Patient Reported Outcomes) at the specified time points
* Able to provide voluntary, informed consent to participate in this study

Exclusion Criteria:

* Diagnosed with angle closure glaucoma in the study eye
* Presence of a secondary glaucoma, pseudoexfoliation glaucoma, or pigmentary glaucoma
* Presence of neovascular, uveitic, or angle recession glaucoma or any glaucoma associate with vascular disorders
* Prior incisional glaucoma surgery, canal-based surgery, suprachoroidal space-based surgery (trabeculectomy, viscocanalostomy, canaloplasty, shunts of any type, collagen implants, etc.) or a cilio-ablative procedure
* Clinically significant inflammation or infection in the study eye within 30 days prior to the baseline visit (e.g. blepharitis, conjunctivitis, keratitis, uveitis, herpes simplex infection)
* History of corneal surgery, corneal opacities, or corneal disease
* Prior intraocular surgery in either eye ≤ 3 months prior to study enrollment with the exception of uncomplicated cataract surgery in either eye ≥ 1 month prior to study enrollment
* Anticipated ocular surgery in either eye within 6 months of baseline
* Concomitant cataract surgery scheduled at the time of glaucoma procedure

The study eye is defined as the eye receiving surgical intervention with either XEN or trabeculectomy.

Patients who have received prior laser trabeculoplasty will be permitted to participate if all other inclusion/exclusion criteria are met.
Prevalence of Osteoporosis in Patients Who Uses Inhaled Steroids

The purpose of this research is to determine whether the prevalence of osteoporosis is greater in patients who suffer from Chronic obstructive pulmonary disease (COPD) or Asthma disease and uses inhaled steroids.


Eligibility Criteria:
Inclusion Criteria:

1. Man at the minimum age of 60 years.
2. Diagnosed with Chronic Obstructive Pulmonary disease (COPD) or Asthma disease.
3. Usage of the following corticosteroids at the minimal doses indicated, for at least 3 years:

Seretide 250/50 mcg Symbicort 320/9 mcg 5.No Diagnosis of thyroid irregularity 6.No diagnosis/treatment for Osteoporosis.

Exclusion Criteria:

1. Usage of systemic steroids more than once during the 12 months prior to the study.
2. Usage of systemic steroids during the month prior to the study.
3. Usage of inhaled steroids in order to treat any other disease except Chronic Obstructive Pulmonary Disease (COPD) or Asthma.
Psychological Intervention for Distress During HSCT

This Phase II trial aims to evaluate a new psychological intervention to alleviate distress during haematopoietic stem cell transplantation (HSCT) together with examining feasibility.

HSCT is a complex procedure aimed at a range of haematological and autoimmune illnesses. Over 3,000 individuals undergo the procedure every year in the UK with substantial benefits. However, it is very costly, intensive, and has a range of debilitating side effects. Consequently, patients often experience considerable distress, which can impede recovery.

A 90-minute, group-based intervention has been developed to address this need based on psychological theory of adjustment to illness-related difficulties. It is delivered by the transplant team and involves provision of information to foster more helpful perceptions about HSCT and facilitating more helpful coping with its difficulties. To evaluate the effectiveness of the intervention in alleviating distress, 60 patients about to undergo HSCT at two sites (Sheffield \& Nottingham) will be randomly allocated into two groups. Patients in the intervention group will receive the new intervention prior to transplantation together with treatment as usual (TAU) while patients in the control group will receive TAU alone. Participants and the researcher collecting the data will be blind to the allocation.

Demographic and relevant clinical information will be recorded at the end of participation to ensure effectiveness of randomisation. For both groups, resilience, distress, coping, and procedure-related perceptions will be measured at four time points: (i) prior to the intervention/transplantation, (ii) day of transplant, (iii) two weeks following the transplant, and (iv) four weeks following the transplant. It is hypothesised that patients in the intervention group will experience higher resilience and lower distress compared to controls and that this difference will be mediated by procedure-related perceptions and coping. A subgroup of participants of those randomised to the group intervention will be invited to participate in a feedback interview at the end.


Eligibility Criteria:
Inclusion Criteria:

* patients referred for HSCT as treatment for haematological malignancy
* age of 18 years or older
* sufficient command of the English language or access to suitable support to comprehend materials and participate in the group and data collection over the telephone
* informed consent
* permission will also be sought by the patient's Consultant Haematologist once clients have consented

Exclusion Criteria:

* Consent withdrawn
* Consultant Haematologist raises concern regarding participation
Cognitive Changes and Rehabilitation in People With Transient Ischemic Attack, Stroke, or Stroke Risk Factors

Stroke is a leading cause of disability; most strokes (80%) are subcortical, with ischemic damage due to occlusion in penetrating arteries. Although ischemic white matter disease (iWMD) may lack gross clinical manifestation, it causes significant cognitive impairment, particularly on measures of executive function, attention, and memory. This impairment is attributable to diffuse damage affecting network connections.

While there are many studies concerning rehabilitation of motor function and language in patients with large focal strokes, few studies have addressed attentional and executive functions. To our knowledge, there are no such studies on iWMD. In this study, patients will be randomized to a novel intervention for improving executive function and a control condition matched for therapist exposure. Patients will be assessed pre-intervention, post-intervention, and at long-term follow-up using a battery of behavioural and neuroimaging tasks. We predict that the novel intervention will be associated with improved executive function, as assessed behaviourally, and improved frontal network function, as assessed through neuroimaging markers.


Eligibility Criteria:
Inclusion Criteria:

* Patients with ischemic white matter disease or small vessel disease, who have experienced a transient ischemic attack, mild stroke, or are at risk of stroke
* Fluent in English
* Able to provide informed consent to all procedures
* Sufficient motor and sensory functioning to complete all study components (with correction or assistance as required)

Exclusion Criteria:

* Substance abuse
* Other psychiatric condition (other than mood, personality, or behaviour change following onset/diagnosis of white matter disease or related condition mentioned above)
* Other medical condition suspected to influence cognition
A Study in Healthy Men to Test How BI 1569912 is Processed in the Body

The main objectives of this trial are:

* To investigate basic pharmacokinetics of BI 1569912 and total radioactivity, including mass balance, excretion pathways and metabolism following oral administration of BI 1569912 (C-14) to healthy male subjects (test treatment, T).
* To investigate the absolute bioavailability of BI 1569912 as single oral solution dose, using a single, concomitant intravenous micro-tracer administration of BI 1569912 (C-13) (reference treatment, R)


Eligibility Criteria:
Inclusion Criteria :

Subjects will only be included in the trial if they meet the following criteria:

1. Healthy male subjects according to the assessment of the investigator, as based on a complete medical history including a physical examination, vital signs (blood pressure (BP), pulse rate (PR)), 12-lead electrocardiogram (ECG), and clinical laboratory tests
2. Age of 18 to 55 years (inclusive)
3. Body mass index (BMI) of 18.5 to 29.9 kg/m 2 (inclusive)
4. Signed and dated written informed consent in accordance with ICH-GCP and local legislation prior to admission to the trial

Exclusion Criteria :

Subjects will not be allowed to participate, if any of the following general criteria apply:

1. Any finding in the medical examination (including BP, PR or ECG) deviating from normal and assessed as clinically relevant by the investigator
2. Repeated measurement of systolic blood pressure outside the range of 90 to 140 mmHg, diastolic blood pressure outside the range of 50 to 90 mmHg, or pulse rate outside the range of 40 to 100 beats per minute (bpm)
3. Any laboratory value outside the reference range that the investigator considers to be of clinical relevance, in particular hepatic parameters (alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin) or renal parameters (creatinine) exceeding the upper limit of normal (ULN) after repeated measurements
4. Any evidence of a concomitant disease assessed as clinically relevant by the investigator
5. Further exclusion criteria apply